_15_11zon.webp)
Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketdailypress.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketDailyPress.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent KRTX Stock Price: $161.33
Summary: Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's product candidate consists of KarXT, for the treatment of acute psychosis in patients with schizophrenia, which are in clinical stage. Karuna Therapeutics Inc. is based in Boston, Massachusetts.
Laura Chico analyst at Wedbush reiterates coverage on Karuna Therapeutics (KRTX) stock in the energy sector with a Buy rating and has not set KRTX's stock price target.
TipRanks.com reports that Karuna Therapeutics currently has 15 analysts offering 12-month price targets on KRTX and the consensus is a Strong Buy rating with an average stock price target of $273.57. The most recent KRTX stock price we have is $161.33 and we are not making any KRTX forecasts at this time.
In addition, TradingView issued a Strong Sell rating for KRTX over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on KRTX. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on KRTX, please click here >>
MoonLake Immunotherapeutics, MLTX
Recent MLTX Stock Price: $22.01
Summary: MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.
Ram Selvaraju analyst at H.C. Wainwright reiterates coverage on MoonLake Immunotherapeutics (MLTX) stock in the energy sector with a Buy rating and has set MLTX's stock price target at $ 28.
TipRanks.com reports that MoonLake Immunotherapeutics currently has 6 analysts offering 12-month price targets on MLTX and the consensus is a Strong Buy rating with an average stock price target of $28.00. The most recent MLTX stock price we have is $22.01 and we are not making any MLTX forecasts at this time.
In addition, TradingView issued a Buy rating for MLTX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MLTX. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MLTX, please click here >>
Altimmune, ALT
Recent ALT Stock Price: $4.95
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
Liisa Bayko analyst at Evercore ISI reiterates coverage on Altimmune (ALT) stock in the energy sector with a Buy rating and has set ALT's stock price target at $ 25.
TipRanks.com reports that Altimmune currently has 8 analysts offering 12-month price targets on ALT and the consensus is a Strong Buy rating with an average stock price target of $27.38. The most recent ALT stock price we have is $4.95 and we are not making any ALT forecasts at this time.
In addition, TradingView issued a Strong Sell rating for ALT over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALT. marketdailypress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ALT, please click here >>
The editors at marketdailypress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketDailyPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to MarketDailyPress.com.
==============================================================================
